Analysis of the Efficacy and Pharmacological Mechanisms of Action of Zhenren Yangzang Decoction on Ulcerative Colitis Using Meta-Analysis and Network Pharmacology

Table 1

Summary of RCTs of ZRYZD for UC.

Study year[ref]	Country	Sample size (experimental/control)	Mean age (years) (experimental/control)	Experimental	Control	Duration
Yuan JY, 2009 [11]	China	88 (44/44)	35.4/33.6	ZRYZD	SASP	6 months
Zhao KH, 2010 [12]	China	35 (19/16)	39.8 ± 14.0/40.2 ± 15.0	ZRYZD	SASP	6 months
Wang L, 2015 [27]	China	80 (40/40)	33.4/34.6	ZRYZD	SASP	4 weeks
Han Y, 2019 [28]	China	63 (32/31)	38.7 ± 7.9/36.6 ± 9.2	ZRYZD	Mesalazine bowel-soluble tablets	6 weeks
Dai AC, 2021 [29]	China	90 (45/45)	39.8 ± 3.16/39.91 ± 3.22	ZRYZD	Mesalazine bowel-soluble tablets	6 weeks

RCT: randomized controlled trial; ZRYZD: Zhen Ren Yang Zang decoction; UC: ulcerative colitis; SASP: sulfasalazine.